This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Garrett-Mayer, E. Search for Related Content PubMed PubMed Citation Articles by Garrett-Mayer, E. Social Bookmarking                   What's this?

The continual reassessment method for dose-finding studies: a tutorial

Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, USA; esg{at}jhu.edu

The Continual Reassessment Method (CRM), along with other adaptive dose-finding study designs, has gained popularity since its proposal by O'Quigley. Several of the reasons it has been embraced by clinical trialists is that it tends to incur fewer toxic events, and more accurately estimate the maximum tolerated dose as compared to the standard Phase I dose escalation designs. Many variations have been published and discussed in the statistical literature, but there has not been as much practical advice for choosing design parameters and implementing the CRM. As a result, the CRM has not been as widely utilized as it could be for dose-finding studies. The goal of this paper is to provide a tutorial for those unfamiliar with the CRM who are either statisticians considering using the CRM for the first time, or investigators with some statistical background. This paper presents the original CRM, and then some of its modified versions. It also explains the specifications that define a CRM design, along with simulated examples of CRMs and standard designs, for illustration.

Clinical Trials, Vol. 3, No. 1, 57-71 (2006)
DOI: 10.1191/1740774506cn134oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Rohatagi, H. Zahir, J. B. Moberly, K. E. Truitt, S.-i. Inaba, T. Shimozato, and T. J. Carrothers Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator J. Clin. Pharmacol., January 1, 2009; 49(1): 50 - 62. [Abstract] [Full Text] [PDF]

				J J. Lee Adaptive Designs for Efficacy and Toxicity Endpoints in Early Drug Development Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 631 - 636. [Abstract] [Full Text] [PDF]